Patient adherence event preview

Announcing its Fifth annual Patient Adherence & Persistence USA Congress, eyeforpharma notes that experts estimate that patient non-adherence costs the pharmaceutical industry in excess of $30.0 billion a year - not to mention the chance at a fuller, healthier life for countless patients. The event is due to take place in October in Philadeplphia, USA. For more information, visit: www.eyeforpharma.com

Commenting, Len Starnes, head of global e-business at Germany-headquartered Bayer Schering, said: "industry awareness of the importance of patient compliance has grown substantially during the last five years. eyeforpharma's 2007 US event is without doubt the one that provided you with both an overview of state-of-the-art approaches and pragmatic industry solution."

Clinical researchers estimate that for most prescribed drugs, patient compliance rates are 50%-60%, but with some disease states, compliance drops as low as 10%-20%. So, even modest improvements in adherence can have significant impacts on not only revenues for drugmakers, but expenses for third-party payers and outcomes for patients, notes eyeforpharma. Improving compliance is a win-win for everyone in the patient-care equation, it adds.